Adjuvant chemotherapy using S-1 plus oxaliplatin (SOX) or tegafur-uracil/leucovorin (UFT/LV) led to similar disease-free survival (DFS) rates in patients with high-risk stage III colon cancer, according to updated results of the ACTS-CC 02* presented at ASCO GI 2019.
Neoadjuvant chemotherapy (NACT) followed by surgery was significantly associated with better disease-free survival (DFS) and overall survival (OS) in patients with LAPC* compared with upfront surgery, according to a study presented at the ASCO Gastrointestinal Cancers Symposium 2019 (ASCO GI 2019).
Adjuvant treatment with durvalumab, a PD-L1 inhibitor, following trimodality therapy may improve relapse-free survival (RFS) in patients with locally advanced oesophageal adenocarcinoma (LA-EAC) or gastroesophageal junction (GEJ) adenocarcinoma who did not achieve pCR* after neoadjuvant chemoradiation, according to a small study presented at the ASCO Gastrointestinal Cancers Symposium 2019 (ASCO GI 2019).
Patients with advanced hepatocellular carcinoma (HCC) and elevated α-fetoprotein concentration who were previously treated with sorafenib had improved overall survival (OS) and progression-free survival (PFS) following treatment with ramucirumab, according to results of the phase III REACH-2* trial.
Responders showed better overall survival (OS) than nonresponders to treatment for hepatocellular carcinoma (HCC), according to an exploratory analysis of the REFLECT trial, suggesting that objective response (OR) is an independent predictor of OS in these patients.
Whether patients had prior gastrectomy did not attenuate the survival benefit conferred by oral trifluridine/tipiracil for those with heavily pretreated metastatic gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, according to new updates from the TAGS study presented at ASCO GI Cancers Symposium (GICS) 2019.
The addition of the monoclonal antibody andecaliximab to nivolumab or a chemotherapy regimen (modified FOLFOX6*) did not provide survival benefit in patients with pretreated metastatic or untreated HER2-negative gastric/gastroesophageal (G/GEJ) adenocarcinoma, according to data presented at ASCO GI 2019.
The addition of the investigational, humanized IgG4* monoclonal antibody tislelizumab to chemotherapy was generally well-tolerated and generated favourable antitumour activity in patients with advanced gastric/gastroesophageal (G/GEJ) cancer and oesophageal squamous cell carcinoma (SCC), according to data presented at ASCO GI 2019.
The combination of paclitaxel and FOLFOX led to an improvement in progression-free survival (PFS) compared with FOLFOX alone among chemotherapy-naïve patients with advanced gastric cancer, according to results from the phase II FNF-004* trial presented at ASCO GI 2019.
Drawing from experience as a key investigator in landmark
clinical trials (including PALOMA, MONALEESA and
MONARCH), and his clinical experience with
CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his
insights into the current evidence of using CDK4/6 inhibitors
to treat HR+/HER2- ABC.